PE-22-28 (CAS 1801959-12-5) is a synthetic seven-amino-acid research peptide developed from investigations into endogenous neuronal signaling pathways. The peptide is derived from studies of the TREK-1 potassium channel, a key regulator of neuronal excitability and serotonergic activity within the central nervous system.
Researchers are investigating PE-22-28 for its ability to modulate neuronal firing patterns, influence serotonin signaling, and support neuroplasticity-related pathways. Unlike many traditional approaches that indirectly affect serotonergic systems, PE-22-28 acts upstream through TREK-1 modulation, producing rapid changes in neuronal excitability in preclinical models.
Animal research has demonstrated increased serotonergic activity alongside enhanced hippocampal neurogenesis, making PE-22-28 a valuable research tool for exploring the relationship between neuronal signaling, cognitive function, stress adaptation, and brain resilience. The peptide's compact seven-amino-acid structure also provides practical advantages for synthesis, purification, and analytical characterization.
Overall, PE-22-28 represents an emerging molecular tool for studying the interaction between ion-channel regulation, neurotransmitter signaling, neuroplasticity, and activity-dependent neuronal adaptation.
PE-22-28 functions primarily through inhibition of the TREK-1 potassium channel, a member of the two-pore-domain potassium channel family expressed in serotonergic neurons of the dorsal raphe nucleus as well as various limbic and cortical brain regions.
Under physiological conditions, TREK-1 generates a background potassium leak current that helps stabilize neuronal membrane potential and limits spontaneous neuronal firing. By reducing potassium efflux through TREK-1, PE-22-28 induces a modest depolarization of the neuronal membrane, increasing the likelihood that neurons reach action-potential threshold.
This enhanced excitability elevates firing rates within serotonergic neurons and promotes calcium influx through voltage-gated calcium channels. Increased intracellular calcium subsequently supports vesicular release of serotonin into projection areas including the prefrontal cortex, hippocampus, and amygdala.
Elevated serotonergic signaling engages multiple downstream receptor systems, particularly 5-HT1A and 5-HT7 receptor populations. Activation of these receptors influences intracellular second-messenger networks involving cyclic adenosine monophosphate (cAMP), protein kinase signaling, and CREB phosphorylation.
CREB activation promotes transcription of brain-derived neurotrophic factor (BDNF), one of the most extensively studied regulators of neuronal plasticity. Increased BDNF expression subsequently activates TrkB receptors and downstream PI3K-Akt and Ras-MAPK signaling cascades.
Akt signaling supports cellular survival pathways while also influencing mTOR-dependent protein synthesis. These processes contribute to increased production of proteins involved in synaptic structure and communication, including PSD-95 and synapsin.
The combined effect is reinforcement of existing synaptic networks, maturation of dendritic spines, enhancement of long-term potentiation, and support for activity-dependent neuronal remodeling.
In parallel, PE-22-28 influences adult hippocampal neurogenesis. Neural progenitor cells located within the dentate gyrus respond to increased network activity and BDNF signaling through enhanced proliferation, survival, and differentiation into mature granule neurons.
Preclinical studies suggest that these neuroplastic adaptations occur on a relatively compressed timeline compared with traditional monoaminergic interventions, making PE-22-28 particularly interesting for investigations involving rapid neuroplasticity mechanisms.
The peptide's short amino-acid sequence also offers significant advantages from a peptide chemistry perspective. Standard solid-phase synthesis techniques achieve high coupling efficiency, excellent purity, and straightforward scale-up while allowing future structural modifications designed to optimize stability or pharmacokinetic properties.
Additional downstream effects observed in experimental systems include activation of cell-survival pathways associated with PI3K-Akt signaling and improved resilience against oxidative and excitotoxic stress within neuronal cultures. Collectively, these molecular actions connect acute modulation of neuronal excitability with longer-term structural and transcriptional adaptations associated with neuroplasticity.
The molecular profile of PE-22-28 positions it as a valuable research tool for studying conditions and biological processes associated with altered serotonergic signaling, impaired neuroplasticity, and reduced hippocampal adaptability.
One of the primary areas of interest involves investigation of brain networks associated with emotional regulation and stress adaptation. Because TREK-1 plays a central role in regulating neuronal excitability within serotonergic circuits, modulation of this channel provides researchers with a unique opportunity to examine how membrane potential influences neurotransmitter release and downstream neuroplastic responses.
The peptide is also being explored in research models focused on hippocampal function. The hippocampus serves as a critical structure involved in learning, memory formation, cognitive flexibility, and adaptation to environmental stressors. Enhanced neurogenesis and synaptic remodeling observed in preclinical models suggest potential relevance for studies investigating age-related cognitive changes, stress-induced neuronal remodeling, and activity-dependent learning mechanisms.
Additional areas of interest include investigation of neuronal resilience under conditions of oxidative stress, inflammation, and excitotoxic challenge. Increased BDNF expression and activation of PI3K-Akt signaling pathways may contribute to cellular adaptations that support neuronal survival and structural integrity in experimental systems.
Researchers are also utilizing PE-22-28 to better understand the relationship between ion-channel regulation and activity-dependent gene expression. The peptide provides a tractable model for examining how changes in neuronal firing patterns influence downstream transcriptional programs associated with synaptic plasticity and network remodeling.
Its compact structure additionally makes PE-22-28 an attractive candidate for medicinal chemistry research, where analog development may be used to investigate improved stability, receptor selectivity, blood-brain barrier penetration, and pharmacokinetic properties while preserving TREK-1 inhibitory activity.
Preclinical research involving PE-22-28 has focused primarily on validated rodent models examining neuronal plasticity, hippocampal neurogenesis, and serotonergic signaling.
In multiple behavioral paradigms, including the forced-swim test and novelty-suppressed feeding model, animals receiving PE-22-28 demonstrated significant changes in behavioral endpoints associated with serotonergic modulation. Notably, these effects appeared within a relatively short timeframe compared with traditional monoaminergic interventions studied under similar experimental conditions.
Chronic stress models have produced particularly interesting findings. In rodents exposed to prolonged corticosterone administration, PE-22-28 reversed several stress-associated behavioral alterations while restoring measures of hippocampal adaptability. Histological analysis revealed substantial increases in BrdU-positive cells within the dentate gyrus after only a few days of peptide exposure, indicating accelerated neurogenic activity.
Molecular investigations further demonstrated elevated hippocampal expression of brain-derived neurotrophic factor (BDNF) together with increased expression of synaptic proteins including PSD-95 and synapsin. These findings support the hypothesis that PE-22-28 influences both structural and functional components of neuronal plasticity.
Studies performed in primary neuronal cultures showed enhanced dendritic spine maturation and increased markers of synaptogenesis. Electrophysiological recordings confirmed that TREK-1 inhibition directly increased firing rates within serotonergic neurons of the dorsal raphe nucleus, establishing a mechanistic link between ion-channel modulation and downstream neurotransmitter signaling.
Comparative investigations with the parent peptide spadin demonstrated that the shortened seven-amino-acid sequence retains strong TREK-1 inhibitory activity while offering practical advantages related to synthesis, purification, and manufacturing consistency.
Across reported preclinical studies, investigators observed no significant evidence of sedation, motor impairment, or overt toxicity under the dosing conditions examined.
At present, no completed human clinical trials have been identified for PE-22-28. Available evidence originates from in-vitro systems and animal research models. Human pharmacokinetic, safety, tolerability, and efficacy data remain unavailable.
As a result, PE-22-28 continues to be regarded as an investigational research peptide requiring additional preclinical characterization and future translational evaluation.
PE-22-28 is particularly interesting because it links rapid changes in neuronal excitability with longer-term structural adaptations associated with neuroplasticity.
The peptide acts at the level of ion-channel regulation by inhibiting TREK-1, producing immediate effects on membrane potential and neuronal firing activity. This initial modulation increases serotonergic signaling throughout interconnected brain networks.
Enhanced serotonergic activity subsequently activates downstream pathways that promote CREB phosphorylation, BDNF expression, and TrkB signaling. These molecular events support synaptic remodeling, dendritic spine maturation, and activity-dependent transcriptional programs associated with neuronal adaptation.
Simultaneously, increased BDNF-TrkB signaling promotes proliferation, survival, and differentiation of neural progenitor cells within the hippocampus. This creates a biological bridge between acute neurotransmitter signaling and longer-term network restructuring.
Unlike approaches that focus exclusively on neurotransmitter availability or receptor activation, PE-22-28 influences multiple interconnected levels of neuronal function. Ion-channel modulation, neurotransmitter release, gene transcription, synaptic remodeling, and neurogenesis become linked within a coordinated signaling cascade.
This integrated mechanism makes PE-22-28 a valuable experimental tool for investigating how changes in neuronal excitability translate into durable adaptations within neural circuits.
Its short peptide sequence further enhances research utility by allowing straightforward synthesis, purification, analytical verification, and future structural optimization. These characteristics position PE-22-28 as both a mechanistic probe and a potential lead structure for future investigations involving neuroplasticity, serotonergic signaling, and activity-dependent brain adaptation.
PE-22-28 is a synthetic seven-amino-acid research peptide developed from studies of the TREK-1 potassium channel and its role in regulating neuronal excitability.
Its molecular mechanisms are associated with:
• TREK-1 potassium channel inhibition
• Increased serotonergic neuronal activity
• BDNF and TrkB pathway activation
• PI3K-Akt and Ras-MAPK signaling
• Synaptic remodeling and dendritic spine maturation
• Adult hippocampal neurogenesis
• Activity-dependent neuroplasticity pathways
As a research peptide, PE-22-28 provides scientists with a unique tool for investigating the relationship between ion-channel modulation, neurotransmitter signaling, neuroplasticity, and neuronal resilience. Ongoing preclinical research continues to explore how TREK-1 regulation influences complex biological processes involved in learning, memory, stress adaptation, and brain function.
Dieser Artikel wird ausschließlich zu Forschungszwecken geliefert.
Alle von PRG bereitgestellten Informationen dienen ausschließlich Bildungs- und Informationszwecken.
Bewährte Verfahren zur Lagerung von Peptiden
Für die Zuverlässigkeit von Laborergebnissen ist die korrekte Lagerung von Peptiden unerlässlich. Geeignete Lagerbedingungen tragen dazu bei, die Stabilität der Peptide über Jahre hinweg zu erhalten und sie vor Kontamination, Oxidation und Abbau zu schützen. Obwohl manche Peptide empfindlicher sind als andere, verlängert die Einhaltung dieser bewährten Verfahren ihre Haltbarkeit und strukturelle Integrität erheblich.
Verhinderung von Oxidations- und Feuchtigkeitsschäden
Peptide können durch den Kontakt mit Feuchtigkeit und Luft beeinträchtigt werden – insbesondere unmittelbar nach der Entnahme aus dem Gefrierschrank.
Lagerung von Peptiden in Lösung
Peptide in Lösung haben eine deutlich kürzere Lebensdauer als in lyophilisierter Form und sind anfällig für bakteriellen Abbau.
Behälter zur Peptidlagerung
Wählen Sie Behälter aus, die sauber, unbeschädigt, chemikalienbeständig und für die Probe geeignet sind.
Regenesis Peptide – Kurztipps zur Lagerung
